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Broad Spectrum of Patients With Chronic Heart Failure
Results From the CHARM (Candesartan in Heart Failure:
Assessment of Reduction in Mortality and morbidity) Program
Objectives The aim of this study was to explore the relationship between baseline resting heart rate and outcomes in pa-
tients with chronic heart failure (HF) according to baseline left ventricular ejection fraction (LVEF) and cardiac
rhythm.
Background Elevated resting heart rate is associated with worse outcomes in patients with HF and reduced LVEF. Whether
this association is also found in patients with HF and preserved LVEF is uncertain, as is the predictive value of
heart rate in patients in atrial fibrillation (AF).
Methods Patients enrolled in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbid-
ity) Program were divided into groups by tertiles of baseline heart rate. Cox proportional hazard models were
used to investigate the association between heart rate and pre-specified outcomes in the overall population as
well as in subgroups defined according to LVEF (40% vs. 40%) and presence (or absence) of AF at baseline.
Results After adjusting for predictors of poor prognosis, patients in the highest heart rate tertile had worse outcomes
when compared with those in the lowest heart rate group (e.g., for the composite of cardiovascular death or HF
hospital stay hazard ratio: 1.23, 95% confidence interval: 1.11 to 1.36, p  0.001). The relationship between
heart rate and outcomes was similar across LVEF categories and was not influenced by beta-blocker use
(p value for interaction 0.10 for both endpoints). However, amongst patients in AF at baseline, heart rate had
no predictive value (p value for interaction 0.001).
Conclusions Resting heart rate is an important predictor of outcome in patients with stable chronic HF without AF, regardless
of LVEF or beta-blocker use. (J Am Coll Cardiol 2012;59:1785–95) © 2012 by the American College of Cardiol-
ogy FoundationElevated resting heart rate is an established risk factor for
cardiovascular mortality and morbidity in a variety of
cardiovascular diseases (1). In patients with reduced left
ventricular ejection fraction (LVEF), with or without signs
or symptoms of heart failure (HF), high heart rate has been
associated with worse outcomes, independently of other
known risk factors (2–6). Several pathophysiologic mecha-
nisms, including blunting of the force-frequency relation-
ship, the induction of myocardial ischemia, precipitation of
rhythm disturbances, and acceleration of atherosclerosis,
See page 1796
have been proposed to explain the association between
higher heart rate and worse outcomes in patients with HF
(1,7). Higher heart rate might also be a marker of greater
From the *Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts; †Division of Cardiology, Department of Internal Medicine, Univer-
sity of Turin, Turin, Italy; ‡Department of Emergency and Cardiovascular Medicine,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; §Hamilton
Health Sciences and McMaster University, Hamilton, Ontario, Canada; Duke
niversity Medical Center, Durham, North Carolina; ¶AstraZeneca LP, Wilming-
on, Delaware; and the #British Heart Foundation Glasgow Cardiovascular Research
entre, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom. The
HARM Program was sponsored by AstraZeneca. No extramural funding was used
o support this work. Drs. Swedberg, Yusuf, Pfeffer, and McMurray have received
esearch grants, honoraria for lectures, and/or consulting fees from AstraZeneca. Dr.
wedberg has received research grants, honoraria or consulting fees from Servier.neurohumoral activation. The recent findings of the SHIFT
(Systolic Heart failure treatment with the If inhibitor
ivabradine Trial) have confirmed the importance of heart
rate in the pathophysiology of HF with reduced LVEF and
have suggested heart rate reduction per se as a mechanism
responsible for improvement of clinical outcomes (8).
Whether higher resting heart rate also has prognostic
importance in patients with HF and preserved LVEF,
representing one-third to one-half of the patients with HF
(9,10), is less well-documented. Furthermore, little is
known about the relationship between heart rate and out-
comes in patients with atrial fibrillation (AF), the preva-
lence of which increases in parallel with the severity of HF
(11). The CHARM (Candesartan in Heart failure: Assess-
ment of Reduction in Mortality and morbidity) Program
enrolled 7,599 patients with a clinical diagnosis of HF,
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tific, Bristol-Myers Squibb, and Concert; and research grants from Amgen, Novartis,
Sanofi-Aventis, AstraZeneca, Baxter, and Celladon. Dr. Michelson is an employee of
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they have no relationships relevant to the contents of this paper to disclose.Manuscript received September 16, 2011; revised manuscript received December 5,
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May 15, 2012:1785–95 Heart Rate and Outcomes in the CHARM Programirrespective of LVEF, and assessed the effect of the angio-
tensin receptor blocker candesartan on cardiovascular mor-
tality and morbidity (12). The main aims of this analysis
were to examine the relationship between resting heart rate
at baseline and fatal and nonfatal cardiovascular outcomes
and all-cause mortality in a broad spectrum of patients with
HF and to determine whether the relationship between
heart rate and outcomes was influenced by LVEF or
underlying cardiac rhythm.
Methods
The CHARM Program. The design, baseline findings, and
verall results of the CHARM Program have been previously
eported in detail (12–14). In brief, 7,599 patients with at least
-week duration of symptomatic HF (New York Heart Asso-
iation [NYHA] functional class II to IV) receiving standard
herapy were enrolled into 1 of 3 component clinical trials
ccording to LVEF and angiotensin-converting enzyme inhib-
tor (ACE-I) treatment: CHARM-Alternative (n  2,028,
VEF 40% and not receiving an ACE-I due to previous
ntolerance), CHARM-Added (n  2,548, LVEF 40%
Baseline Characteristics of the Overall CHARMAccording to Group Defined by Ts of Baseline HTable 1 B seline Charact ristics of the OveAccording to Group Defined by Ts o
Heart Rate G
T1
n  2,553
(33.6%)
60 (57–64)*
Patient characteristics
Age 67 (59–74)
75 yrs 609 (23.9)
Female 692 (27.1)
LVEF (%) 38 (30–50)
NYHA functional class
II 1,260 (49.4)
III/IV 1,293 (50.7)
AF on ECG 283 (11.1)
Blood pressure (mm Hg)
Systolic 130 (118–142)
Diastolic 75 (70–80)
Medical history
Current smoking 305 (11.9)
Diabetes mellitus 601 (23.5)
Hypertension 1,365 (53.5)
Hospital admission for HF 1,691 (66.2)
Myocardial infarction 1,510 (59.2)
Stroke 238 (9.3)
History of AF 673 (26.4)
Medical treatment
ACE inhibitors 1,054 (41.3)
Beta-blockers 1,769 (69.3)
Diuretic agents 2,031 (79.6)
Spironolactone 369 (14.5)
Digoxin/digitalis glycosides 962 (37.7)
Values are median (interquartile range) or n (%). *Median heart rate (
ACE  angiotensin-converting enzyme; AF  atrial fibrillation; ECG  ele
fraction; NYHA  New York Heart Association functional class; T  tertile.eceiving ACE-I treatment), and
he CHARM-Preserved study
n  3,023, LVEF 40%) (15–
7). Important exclusion criteria
ere serum creatinine 3 mg/dl
265 mol/l) or more; serum po-
assium 5.5 mmol/l or more;
nown bilateral renal artery steno-
is; symptomatic hypotension;
ritical aortic or mitral stenosis; or
ecent (in the previous 4 weeks)
yocardial infarction, stroke, or
eart surgery. Within each of the
omponent trials, patients were randomly allocated to cande-
artan or matching placebo, initiated at 4 mg or 8 mg (at the
iscretion of the investigator) once daily at the enrollment visit.
he dose was increased toward the target dose (32 mg once
aily) in a stepwise fashion as tolerated but not faster than every
weeks. Because the rate of recruitment varied between the
HARM trials, follow-up ranged from a median of 34
onths in CHARM-Alternative and 37 months in the
lationateHARM Population
eline Heart Rate
t Baseline (beats/min)
p Value for Trend
T2 T3
2,689 n  2,355
5.4%) (31.0%)
70–75)* 85 (80–91)*
(58–74) 65 (57–73) 0.001
(23.2) 503 (21.4) 0.04
(33.7) 802 (34.1) 0.001
(28–50) 35 (25–47) 0.001
(44.7) 953 (40.5)
(55.3) 1,402 (59.5) 0.001
(14.8) 467 (19.8) 0.001
(120–142) 130 (118–144) 0.22
(70–84) 80 (70–85) 0.001
(14.1) 431 (18.3) 0.008
(29.3) 772 (32.8) 0.001
(56.9) 1,290 (54.8) 0.33
(72.3) 1,789 (76.0) 0.001
(53.3) 1,059 (45.0) 0.001
(8.9) 187 (7.9) 0.09
(27.7) 664 (28.2) 0.15
(40.8) 973 (41.3) 0.99
(53.7) 988 (42.0) 0.001
(81.9) 2,051 (87.1) 0.001
(16.1) 470 (20.0) 0.001
(43.0) 1,136 (48.2) 0.001
artile range).
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
AF  atrial fibrillation
ECG  electrocardiogram
HF  heart failure
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
AssociationPopueart Rr ll C
f Bas
roup a
n 
(3
72 (
67
625
905
37
1,202
1,487
398
130
80
378
789
1,529
1,945
1,433
238
746
1,098
1,445
2,202
432
1,156
interqu
ctrocardiogram; HF  heart failure; LVEF  left ventricular ejection
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(38 months in the overall CHARM Program).
Baseline heart rate measurement and outcomes evaluated.
All patients enrolled in the CHARM Program had baseline
heart rate measured by the site investigator at the randomiza-
tion visit, in accordance with the protocol and standard
operating procedures. After a resting period of 5 min, heart rate
was either assessed by palpation for at least 30 s or from
auscultation of the heart or from electrocardiogram (ECG). In
addition, a 12-lead ECG was recorded in all patients and
interpreted by investigators at each participating center with a
structured report taking into account, among others, the
presence or absence of AF. In patients for whom both pieces of
information were available, we examined the association be-
tween baseline resting heart rate, heart rhythm (determined by
the baseline ECG) and all-cause death (the primary outcome
of the entire CHARM Program), and the composite outcome
of cardiovascular death or hospital stay for the management of
worsening HF (the primary outcome of each component trial).
All endpoints were adjudicated in a blinded fashion. Deaths
were considered to be cardiovascular unless another clear cause
was apparent. Treatment in hospital for worsening HF was
Baseline Characteristics According to Group Defined by Ts ofHe t Rate in Patients With Reduced and Preserved LVEFTable 2 B seline Chara teristics According to Group D fined bBaseline Heart Rate in Patients With Reduced and Pre
Reduced LVEF
T1 T2 T3
n  1,414 n  1,617 n  1
(30.9%) (35.3%) (33.8
60 (58–64)* 72 (70–76)* 86 (80–
Patient characteristics
Age 66 (58–74) 67 (58–73) 65 (56
75 yrs 311 (22.0) 329 (20.4) 290 (18
Female 303 (21.4) 447 (27.6) 438 (28
LVEF (%) 30 (25–35) 30 (24–35) 29 (22
NYHA functional class
II 536 (37.9) 561 (34.7) 483 (31
III/IV 878 (62.1) 1056 (65.3) 1,062 (68
Blood pressure (mm Hg)
Systolic 125 (110–140) 126 (114–140) 128 (11
Diastolic 75 (68–80) 77 (70–80) 80 (70
Medical history
Current smoking 171 (12.1) 230 (14.2) 304 (19
Diabetes mellitus 311 (22.0) 486 (30.1) 509 (32
Hypertension 650 (46.0) 812 (50.2) 781 (50
Hospital admission for HF 981 (69.4) 1,186 (73.4) 1,183 (76
Myocardial infarction 917 (64.9) 968 (59.9) 779 (50
Stroke 130 (9.2) 141 (8.7) 124 (8.
History of AF 366 (25.9) 444 (27.5) 393 (25
Medical treatment
ACE inhibitors 808 (57.1) 903 (55.8) 838 (54
Beta-blockers 984 (69.6) 868 (53.7) 667 (43
Diuretic agents 1,206 (85.3) 1,411 (87.3) 1,410 (91
Spironolactone 247 (17.5) 303 (18.7) 370 (24
Digoxin/digitalis glycosides 699 (49.4) 845 (52.3) 868 (56Values are median (interquartile range) or n (%). *Median heart rate (interquartile range).
Abbreviations as in Table 1.defined as an unplanned admission that was necessitated by
HF and required intravenous diuretic agents.
Statistical analysis. To illustrate the relationship between
resting heart rate and baseline characteristics, we divided
patients into groups by tertiles of heart rate. Tertiles were
chosen according to the resting heart rate distribution at
baseline. Each of these heart rate bands was centered round
a multiple of 10, because we observed a substantial “digit
preference” for investigator-reported heart rate. Differences
in baseline characteristics across tertiles of baseline heart
rate were assessed with a test for trend by means of variance
weighted least square regression for continuous variables
and with a nonparametric test for trend (18) for categorical
variables in the overall CHARM population as well as in
subgroups defined according to LVEF (i.e., reduced vs.
preserved) and heart rhythm (presence or absence of AF).
Kaplan-Meier survival analysis stratified according to ter-
tiles of baseline heart rate for death from any cause and for
the composite of cardiovascular death or hospital stay for
worsening HF were determined and presented as event
curves, compared by means of log-rank test. Incidence rates
were calculated/100 person-years. The association be-
of
d LVEF
Preserved LVEF
p Value
for Trend
T1 T2 T3
p Value
for Trend
n  1,060 n  1,037 n  924
(35.1%) (34.3%) (30.6%)
60 (56–63)* 71 (68–74)* 84 (80–90)*
0.001 68 (61–75) 68 (59–75) 68 (58–75) 0.03
0.03 281 (26.5) 275 (26.5) 251 (27.2) 0.75
0.001 360 (34.0) 429 (41.4) 422 (45.7) 0.001
0.001 53 (46–60) 52 (46–60) 53 (46–60) 0.73
672 (63.4) 630 (60.8) 533 (57.7)
0.001 388 (36.6) 407 (39.3) 391 (42.3) 0.01
) 0.09 135 (120–150) 135 (120–150) 140 (124–150) 0.007
0.001 78 (70–82) 80 (70–86) 80 (70–88) 0.001
0.01 127 (12.0) 139 (13.4) 143 (15.5) 0.72
0.001 269 (25.4) 297 (28.6) 290 (31.4) 0.003
0.01 660 (62.3) 690 (66.5) 591 (64.0) 0.39
0.001 651 (61.4) 736 (71.0) 688 (74.5) 0.001
0.001 555 (52.4) 459 (44.3) 324 (35.1) 0.001
0.26 98 (9.3) 93 (9.0) 77 (8.3) 0.48
0.76 286 (27.0) 292 (28.2) 302 (32.7) 0.006
0.11 226 (21.3) 192 (18.5) 158 (17.1) 0.02
0.001 736 (69.4) 578 (55.7) 369 (39.9) 0.001
0.001 764 (72.1) 760 (73.3) 733 (79.3) 0.001
0.001 112 (10.6) 126 (12.2) 113 (12.2) 0.24
0.001 241 (22.7) 293 (28.3) 308 (33.3) 0.001y Ts
serve
,545
%)
92)*
–72)
.8)
.4)
–35)
.3)
.7)
3–140
–85)
.7)
.9)
.6)
.6)
.4)
0)
.4)
.2)
.2)
.3)
.0)
.2)
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May 15, 2012:1785–95 Heart Rate and Outcomes in the CHARM Programtween baseline heart rate and risk was assessed with either
univariate and multivariable Cox proportional hazards
models, fitting heart rate both as a continuous (hazard
ratio for each 10-beats/min change in heart rate) and as
a categorical variable (hazard ratio calculated for the
lowest tertile as reference). Multivariable analysis ad-
justed for the 10 strongest predictors of outcome, as
expressed by decreasing chi-square statistic, previously
identified in the CHARM Program (19): age (years),
LVEF, diabetes, previous HF hospital stay, NYHA
functional class, body mass index, diastolic blood pres-
sure, sex, radiologic cardiomegaly (defined as a cardio-
thoracic ratio 0.5 at chest x-ray), and candesartan
treatment. In addition, beta-blocker use at baseline was
added into the model, because of the direct heart rate-
lowering effect of beta-blockers and because of their
beneficial effect on morbidity and mortality in patients
with HF. The proportional hazards assumption was
checked both graphically and by means of scaled Schoe-
nfeld residuals. Interaction testing was used to assess
whether the relation between baseline heart rate and
outcome was modified by LVEF (modeled either as a
continuous variable or categorized 40% vs. 40%) and
Baseline Characteristics According to Group Defined by Ts of BaseTable 3 Baseline Characteristics According to Group Defined b
No AF at Randomization
T1 T2 T3
n  2,270 n  2,058 n  2
(35.2%) (31.9%) (32.9
60 (57–64)* 72 (70–74)* 84 (80–
Patient characteristics
Age 67 (59–74) 67 (57–73) 65 (56
75 yrs 519 (22.9) 429 (20.9) 414 (19
Female 636 (28.0) 684 (33.2) 731 (34
LVEF (%) 38 (30–50) 37 (28–50) 35 (25
NYHA functional class
II 1,151 (50.7) 949 (46.1) 853 (40
III/IV 1,119 (49.3) 1,109 (53.9) 1,268 (59
Blood pressure (mm Hg)
Systolic 130 (120–142) 130 (120–142) 130 (11
Diastolic 75 (70–80) 80 (70–84) 80 (70
Medical history
Current smoking 276 (12.2) 310 (15.1) 390 (18
Diabetes mellitus 531 (23.4) 613 (29.8) 732 (34
Hypertension 1,217 (53.6) 1,153 (56.0) 1,174 (55
Hospital admission for HF 1,466 (64.6) 1,458 (70.9) 1,572 (74
Myocardial infarction 1,393 (61.4) 1,176 (57.1) 1,024 (48
Stroke 211 (9.3) 165 (8.0) 166 (7.
History of AF 406 (17.9) 328 (15.9) 252 (11
Medical treatment
ACE inhibitors 911 (40.1) 829 (40.3) 911 (43
Beta-blockers 1,627 (71.7) 1,143 (55.5) 884 (41
Diuretic agents 1,764 (77.7) 1,638 (79.6) 1,820 (85
Spironolactone 311 (13.7) 297 (14.4) 405 (19
Digoxin/digitalis glycosides 754 (33.2) 773 (37.6) 881 (41Values are median (interquartile range) or n (%). *Median heart rate (interquartile range).
Abbreviations as in Table 1.beta-blocker use at randomization. Formal interaction
testing was also used to ascertain whether the relation
between baseline heart rate and outcomes differed in
specific subgroups: patients with and without AF, dia-
betic and non-diabetic patients, current smokers and
non-smokers. Continuous variables were expressed as
medians and interquartile ranges (IQR), and categorical
variables were expressed as counts and percentages. All p
values were 2-sided, and p  0.05 was used to determine
statistical significance, except for tests for interaction, for
which p  0.10 was used. Analyses were all based on
intention-to-treat and were performed with STATA
(version 11.2, StataCorp LP, College Station, Texas).
Results
Baseline characteristics. Information about baseline rest-
ing heart rate and rhythm were available for 7,597 (99.9%)
participants in the CHARM Program, and the median
heart rate overall was 72 beats/min (IQR 64 to 80). Baseline
demographic and clinical characteristics in the overall
CHARM population grouped by tertiles of baseline heart
rate are shown in Table 1. Patients with a higher heart rate
eart Rate in Patients Without and With AFof Baseline Heart Rate in Patients ithout and With AF
AF at Randomization
p Value
for Trend
T1 T2 T3
p Value
for Trend
n  453 n  352 n  343
(39.5%) (30.7%) (29.9%)
64 (60–68)* 76 (72–80)* 90 (86–100)*
0.001 70 (64–76) 70 (63–77) 69 (61–75) 0.009
0.007 149 (32.9) 125 (35.5) 101 (29.5) 0.36
0.001 109 (24.1) 127 (36.1) 112 (32.7) 0.005
0.001 37 (28–50) 38 (29–51) 38 (29–50) 0.94
174 (38.4) 136 (38.6) 152 (44.3)
0.001 279 (61.6) 216 (61.4) 191 (55.7) 0.11
) 0.57 130 (112–140) 130 (120–145) 130 (120–145) 0.005
0.001 75 (70–82) 80 (70–85) 80 (70–90) 0.001
0.001 44 (9.7) 38 (10.8) 56 (16.3) 0.93
0.001 112 (24.7) 91 (25.9) 83 (24.2) 0.90
0.24 247 (54.5) 201 (57.1) 192 (56.0) 0.65
0.001 358 (79.0) 291 (82.7) 280 (81.6) 0.32
0.001 183 (40.4) 109 (31.0) 117 (34.1) 0.05
0.08 49 (10.8) 37 (10.5) 35 (10.2) 0.78
0.001 432 (95.4) 335 (95.2) 330 (96.2) 0.59
0.06 227 (50.1) 128 (36.4) 119 (34.7) 0.001
0.001 229 (50.6) 156 (44.3) 163 (47.5) 0.34
0.001 422 (93.2) 324 (92.1) 316 (92.1) 0.57
0.001 105 (23.2) 83 (23.6) 70 (20.4) 0.38
0.001 330 (72.9) 265 (75.3) 251 (73.2) 0.87line Hy Ts
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smoker. A higher resting heart rate was also associated with
lower LVEF and with higher diastolic blood pressure and
NYHA functional class. More patients in the highest heart
rate tertile had been previously admitted to hospital because
of HF decompensation, compared with patients in the 2
lower heart rate tertiles. By contrast, patients in the highest
heart rate group were less likely to have suffered from
myocardial infarction, compared with patients in the other
groups. The proportion of patients treated with a beta-
blocker decreased as heart rate increased, whereas the use of
a diuretic, spironolactone, and digoxin increased with in-
creasing heart rate. In patients with reduced and preserved
LVEF as well as in those without AF at baseline, the
distribution of baseline characteristics across tertiles of heart
rate was similar to that observed in the overall population
(Tables 2 and 3). However, some of the differences between
heart rate tertiles seen in these other subgroups were not
present in patients with AF (Table 3). In particular, there
was no gradient in LVEF, NYHA functional class, or
history of diabetes. There was also no gradient in history of
hospital stay for HF or in use of diuretic agents or digoxin,
although the frequency of each of these was higher in
patients with AF (irrespective of heart rate) than in patients
without AF (Table 3).
Baseline heart rate and all-cause mortality. In the overall
CHARM population, during a median follow-up of 37.7
months, 1,831 patients (24.1%) died. Individuals with a
higher heart rate at baseline had a greater risk of death from
any cause, compared with those with a lower heart rate
(overall log-rank test p value 0.001) (Fig. 1A). Beta-
blocker use at randomization was associated with a lower
risk of death but did not change the association between
heart rate and mortality (p for interaction 0.55) (Fig. 2A).
The relationship between heart rate and mortality (and
cardiovascular death or HF hospital stay) was also observed
when beta-blocker dose was taken into consideration
(higher heart rate was associated with worse outcomes
whether or not patients were taking50% of recommended
dose or median dose). The absolute death rate/100
patient-years of follow-up in patients with reduced LVEF
was approximately double that in patients with preserved
LVEF, but a concordant increment in death rates was seen
with increasing heart rate in each of the 2 LVEF categories
(Fig. 3A and Table 4). Similarly, the unadjusted risk of
death showed a concordant increase across tertiles of heart
rate irrespective of LVEF (p for interaction with continuous
LVEF  0.80; p for interaction with categorical LVEF 
.68) (Fig. 4A); the findings were similar if LVEF was
ichotomized at 50% rather than 40% in the categorical
nalysis (and this was also true for the outcome of
ardiovascular death or HF hospital stay). The associa-
ion between higher heart rate and the risk of death
emained significant in a multivariable model that ad-
usted for the covariates listed in the Methods in both
VEF subgroups (Table 4); adding baseline treatment, ancluding ACE-inhibitors, beta-blockers, diuretic agents,
pironolactone, and digitalis glycosides, to the multivari-
ble model did not change this finding. For each addi-
ional 10-beat increase there was—treating baseline heart
ate as a linear continuous variable—a 6% and 5%
djusted risk accrual in patients with reduced and pre-
erved LVEF, respectively (Table 4).
When heart rhythm at randomization was taken into
ccount, the association between higher heart rate and
he risk of death was confirmed in patients without AF
ut not in those with AF at baseline (p for interaction
0.001) (Fig. 5A and Table 4). A 10-beat increase in
eart rate was associated with—modeling heart rate as a
inear continuous variable—an 8% increase in the risk of
eath in patients without AF, but no significant increase
n risk was observed in patients with AF (Table 4). The
Figure 1 Kaplan-Meier Survival Analysis
According to Baseline Heart Rate
Event curves for all-cause mortality (A) and for the composite outcome of
cardiovascular (CV) death or hospital stay for worsening heart failure (WHFH)
(B) according to tertiles (Ts) of baseline heart rate in the overall CHARM
population.ssociation between a higher baseline heart rate and a
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and smoking status (p for interaction between heart rate
and diabetes  0.47; p for interaction between heart rate
nd smoking status  0.33).
aseline heart rate and cardiovascular death or hospital
tay for worsening HF. Patients with a higher heart rate at
aseline had a higher incidence of the composite outcome of
ardiovascular death or HF hospital stay (overall log-rank
est p value 0.001) (Fig. 1B). The association between
igher heart rate and the risk of the composite outcome was
bserved independently of beta-blocker use at baseline (p
or interaction  0.77) (Fig. 2B). A similar pattern of
ncrease in event rate across heart rate tertiles was seen in
oth the reduced and preserved LVEF groups (Fig. 3B,
able 4). This finding was confirmed in the univariate and
ultivariable analysis, where an increase in the risk of
ardiovascular death or HF hospital stay was observed with
ncreasing heart rate regardless of baseline LVEF (p for
Figure 2
Kaplan-Meier Survival Analysis According to
Baseline Heart Rate, Stratified by Beta-Blocker
Use at Baseline
Event curves for all-cause mortality (A) and for the composite outcome of CV
death or WHFH (B) according to Ts of baseline heart rate, stratified by beta-
blocker use at baseline (dashed line  no beta-blocker use at randomization,
solid line  beta blocker use at randomization) in the overall CHARM popula-
tion. p value refers to the test for interaction between baseline heart rate and
beta-blocker use at baseline. Abbreviations as in Figure 1.nteraction with continuous LVEF 0.88; p for interactionith categorical LVEF  0.96) (Fig. 4B, Table 4). Adding
baseline treatment, including ACE inhibitors, beta-
blockers, diuretic agents, spironolactone and digitalis glyco-
sides, to the multivariable model did not change this
finding. With baseline heart rate as a continuous variable, a
10-beat increase in heart rate was associated with a 7% and
with a 6% increase in the risk of the composite endpoint in
patients with reduced and preserved LVEF, respectively
(Table 4).
The prognostic importance of heart rate was confirmed in
patients without AF at baseline either modeling heart rate
as a categorical (adjusted hazard ratio: 1.28, confidence
interval: 1.14 to 1.44 for patients in the highest heart rate
tertile) or as a continuous variable (adjusted hazard ratio:
1.10, confidence interval: 1.06 to 1.13 for each 10-beat
increase in heart rate). By contrast, in patients with AF at
baseline, there was no association between heart rate and the
risk of the composite outcome (p value for interaction
between heart rate and the presence of AF 0.001) (Fig.
5B, Table 4). This conclusion was not altered by adding
Figure 3 Event Rates in Patients With Preserved and
Reduced LVEF According to Baseline Heart Rate
All-cause mortality (A) and CV death or WHFH (B) event rates (per 100-patient
years) according to Ts of baseline heart rate in patients with preserved (blue)
and reduced (red) left ventricular ejection fraction (LVEF). Abbreviations as in
Figure 1.
other a
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Heart Rate and Outcomes in the CHARM Program May 15, 2012:1785–95digoxin to the multivariable model. Although higher event
rates were observed with increasing heart rate, the associa-
tion between a higher heart rate and a higher risk of
cardiovascular death or HF hospital stay seemed stronger in
nondiabetic subjects than in diabetic subjects (p for inter-
action between heart rate and diabetes  0.01) A possible
interaction between heart rate and current smoking was also
observed (p  0.07).
Effect of candesartan and baseline heart rate. Although
candesartan did not reduce mortality overall in the CHARM
Program, there was a nominally significant interaction between
heart rate at baseline and the effect of candesartan on all-cause
mortality (p value for interaction  0.04), with an apparent
reduction in mortality only in patients in the highest heart
rate-tertile (data not shown). This interaction was not seen for
the composite of cardiovascular death or HF hospital stay (p
0.24), for which there were many more events and which was
reduced, overall, by candesartan.
Discussion
The CHARM dataset provided a unique opportunity to
examine the relationship between baseline resting heart rate
Event Rates, Adjusted HRs Across Ts of Heart Rate and Adjusted HRsfor All-Cau e Mortality and fo CV Death or WHFHTable 4 Event Rates, Adjusted HRs Across Ts of Heart Rat andfor All-Cause Mortality and for CV Death or WHFH
All-Cause Mortality
Event Rates (95% CI)/
100 Patient-Yrs HR (95% CI)*
HR (95%
10-Beats/Min
Overall
T1 7.2 (6.6–7.8) 1.00
T2 8.3 (7.7–9.0) 1.07 (0.95–1.20)
T3 10.2 (9.4–11.0) 1.27 (1.13–1.43)
All patients — — 1.06 (1.02
Reduced LVEF
T1 8.9 (8.0–9.8) 1.00
T2 10.5 (9.6–11.5) 1.10 (0.96–1.27)
T3 12.2 (11.2–13.3) 1.26 (1.09–1.45)
All patients — — 1.06 (1.02
Preserved LVEF
T1 5.0 (4.3–5.8) 1.00
T2 5.2 (4.4–6.1) 1.05 (0.84–1.32)
T3 6.3 (5.4–7.3) 1.25 (0.99–1.58)
All patients — — 1.05 (0.98
No AF
T1 6.7 (6.1–7.4) 1.00
T2 7.7 (7.0–8.5) 1.08 (0.94–1.23)
T3 9.5 (8.8–10.4) 1.26 (1.10–1.43)
All patients — — 1.08 (1.04
AF
T1 11.6 (9.8–13.6) 1.00
T2 13.0 (10.9–15.5) 1.15 (0.90–1.48)
T3 10.3 (8.4–12.5) 0.97 (0.75–1.26)
All patients — — 0.97 (0.90
*Model is adjusted for age, LVEF, diabetes, bodymass index, previous HF hospital stay, sex, NYHA fu
use at baseline.
CI  confidence interval; HR  hazard ratio; WHFH  hospital stay for worsening heart failure;and outcomes in a large cohort of patients with a wide rangeof LVEF and receiving contemporary management for
symptomatic HF. Our analysis confirmed the predictive
value of resting heart rate in patients with HF and sinus
rhythm, for both the composite outcome of cardiovascular
death or HF hospital stay and all-cause mortality. The
greater risk of events in patients with higher heart rate was
observed across the full spectrum of LVEF and persisted
even after adjustment for other recognized predictors of
mortality and morbidity. Moreover, the relationship be-
tween heart rate and outcomes in patients with sinus rhythm
was not modified by the use of beta-blockers at baseline.
Interestingly, however, higher heart rate was not related to
outcome in patients with AF.
Heart rate as a risk marker in patients with HF. Certain
variables previously reported to be associated with worse
outcomes in HF (e.g., diabetes, higher NYHA functional
class, lower LVEF, and a history of HF hospital stay) were
more frequent in patients with a higher heart rate at
baseline, but other variables associated with a better
outcome were also more common in patients with a
higher heart rate (e.g., younger age, female sex, and lower
frequency of prior myocardial infarction). The baseline
ach 10-Beats/Min Increase in Baseline Heart Rateted HRs for Each 10-Beat /Min Increase in Baseline Heart Rate
CV Death or WHFH
ase*
Event Rates (95% CI)/
100 Patient-Yrs HR (95% CI)*
HR (95% CI)/
10-Beats/Min Increase*
10.3 (9.5–11.1) 1.00
12.8 (12.0–13.7) 1.11 (1.01–1.23)
15.3 (14.3–16.4) 1.23 (1.11–1.36)
) — — 1.07 (1.04–1.10)
12.5 (11.5–13.7) 1.00
15.8 (14.6–17.1) 1.15 (1.01–1.30)
18.4 (17.0–19.8) 1.25 (1.11–1.42)
) — — 1.07 (1.03–1.10)
7.4 (6.5–8.4) 1.00
8.9 (7.8–10.0) 1.14 (0.94–1.37)
9.8 (8.6–11.1) 1.14 (0.93–1.38)
) — — 1.06 (1.00–1.12)
9.4 (8.7–10.2) 1.00
12.0 (11.1–13.0) 1.14 (1.02–1.28)
15.0 (14.0–16.1) 1.28 (1.14–1.44)
) — — 1.10 (1.06–1.13)
18.3 (15.9–21.1) 1.00
17.5 (14.9–20.6) 0.97 (0.78–1.21)
14.3 (12.0–17.1) 0.85 (0.67–1.07)
) — — 0.95 (0.89–1.02)
l class, radiologic cardiomegaly, diastolic blood pressure, randomized treatment, and beta-blocker
bbreviations as in Table 1.for EAdjus
CI)/
Incre
–1.10
–1.10
–1.12
–1.12
–1.05
nctionause of beta-blockers was also lower in patients with
1793JACC Vol. 59, No. 20, 2012 Castagno et al.
May 15, 2012:1785–95 Heart Rate and Outcomes in the CHARM Programhigher heart rate, possibly because these individuals had
worse overall clinical status or fewer indications for
beta-blockers. In addition, higher heart rate might also
reflect unmeasured variance such as neuroendocrine ac-
tivity, particularly sympathetic activity (or sympathetic-
parasympathetic imbalance). However, heart rate re-
mained an independent predictor of outcome in a
multivariable analysis taking into account these imbal-
ances, and no interaction between baseline heart rate and
beta-blocker use was observed.
Association between heart rate and outcomes across the
continuum of LVEF. We found no interaction between
Figure 4 Association Between Baseline Heart
Rate and Outcomes by Subgroups of LVEF
Unadjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause
mortality (A) and for CV death or WHFH (B) across Ts of baseline heart rate;
p values for interaction between heart rate and LVEF treated as linear continu-
ous variables are shown. Abbreviations as in Figures 1 to 3.resting heart rate and LVEF, indicating that the value ofelevated heart rate in predicting worse outcomes was inde-
pendent of baseline left ventricular systolic function in
patients with HF. Despite the epidemiologic importance of
HF with preserved LVEF, only 2 other studies have
examined the association between baseline heart rate and
outcomes in this subgroup of patients. In a post hoc analysis
of the DIG (Digitalis Investigation Group) trial, a higher
heart rate was associated with a greater risk of HF hospital
stay both in patients with reduced and preserved LVEF.
However, an association between higher heart rate and
higher mortality was only seen in patients with a reduced
LVEF (20). The discrepancy between these findings and
ours warrants further investigations but might be due to
Figure 5 Association Between Baseline Heart Rate
and Outcomes by Baseline Cardiac Rhythm
Unadjusted HRs and 95% CIs for all-cause mortality (A) and for CV death or
WHFH (B) across Ts of baseline heart rate; p values for interaction between
heart rate treated as a linear continuous variable and baseline rhythm (sinus
rhythm vs. atrial fibrillation) are shown. Abbreviations as in Figures 1 to 4.
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Heart Rate and Outcomes in the CHARM Program May 15, 2012:1785–95differences between the studies. Beta-blockers were not used
to treat HF at the time of the DIG trial, and patients in that
trial had an LVEF45% (compared with 40% in CHARM).
erhaps, most importantly, the DIG preserved LVEF
ncillary trial was a much smaller than the CHARM-
reserved study, resulting in considerably fewer deaths in
his subset of patients in the DIG trial (i.e., 231 vs. 364 in
he CHARM-Preserved study) and greater statistical power
n the CHARM-Preserved study. Nevertheless, further
xamination of the relationship between heart rate and
utcomes in HF with preserved LVEF is needed before any
efinitive conclusion can be drawn. Recently, Kapoor et al.
21) reported that high resting heart rate was associated
ith worse survival among 685 consecutive patients with
reserved systolic function (with 278 deaths overall). How-
ver, this cohort was unusual in that 97% of the patients
ere male.
he prognostic value of heart rate according to baseline
ardiac rhythm. An interesting finding of our analysis was
he lack of predictive value of higher heart rate in patients
ith AF at baseline. Although the number of patients and
vents was much smaller in the AF subgroup, the highly
ignificant interaction between heart rhythm and the rela-
ionship between heart rate and outcomes suggests that this
nding is a true one. Moreover, a similar observation was
ade in a cohort of patients with acute HF, in which a higher
eart rate was associated with a significantly lower all-cause
nd cardiovascular mortality in those with AF (22). In another
tudy of patients with moderate-to-severe chronic HF and
oncomitant AF, a lower heart rate at baseline was associated
ith a worse prognosis (23). The explanation for this appar-
ntly paradoxical finding in patients with AF (compared with
hose in sinus rhythm) is uncertain. Although in patients with
F and in sinus rhythm a higher heart rate could be a marker
f greater neurohumoral activation (24) or significant auto-
omic impairment (25), this might not be so in those with AF.
urthermore, systematic underestimation of the ventricular
ate might have occurred in patients with AF when the rate
as assessed by palpation or auscultation. Conversely, a true
ow ventricular rate might indicate conducting system disease,
tself a poor prognostic feature. In patients with AF, a higher
entricular rate might be a compensatory response to the
eduction in cardiac output due to loss of effective atrial
ontraction (26).
he prognostic value of heart rate according to diabetic
nd smoking status. Although both diabetic and nondia-
etic patients showed increasing event rates with increasing
eart rate, the association between a high heart rate and the
isk of the primary composite outcome (cardiovascular death
r HF hospital stay) seemed to be stronger in nondiabetic
han in diabetic patients. For the same outcome, a similar
gure was observed in nonsmokers as compared with
urrent smokers. The imbalance between sympathetic/
arasympathetic systems associated with cardiac autonomic
europathy in diabetic subjects and the increased sympa-
hetic outflow induced by smoking are possible explanationsor these findings (27,28). However, multiple interaction
ests were conducted with the possibility of a nominally
ignificant interaction occurring by chance alone (29).
trengths and limitations. One of the main strengths of
he present study is the wide spectrum of LVEF across
hich the prognostic impact of heart rate was investigated.
n addition, the modern HF treatment used in the CHARM
rogram—especially beta-blockers—in more than one-half
f the patients makes our results more generalizable to real
linical practice, compared with previous reports (5,20).
ome limitations of the present analysis should also be
cknowledged. We relied on investigator-reported baseline
eart rate, which was probably measured in different ways,
t different times of day, and under different circumstances.
stimation of the average ventricular rate in patients with
F was probably less reliable than measurement of heart
ate in those in sinus rhythm. Similarly, patients were
lassified as having AF or no AF according to the investi-
ator interpretation of their baseline ECG. In addition, we
id not use serial assessments of heart rate over time for the
rediction of risk.
onclusions
n patients with stable chronic symptomatic HF and with-
ut AF, resting heart rate is a powerful predictor of
ortality and cardiovascular outcomes, irrespective of
VEF, treatment with beta-blockers, and other important
rognostic factors. This easily measured clinical variable
ould be used in the risk stratification of these patients in
veryday clinical practice.
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